We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PetMed Rides on Solid Reorders & New Orders Amid Competition
Read MoreHide Full Article
On Dec 29, we issued an updated research report on PetMed Express, Inc. (PETS - Free Report) . The stock sports a Zacks Rank #1 (Strong Buy).
Over the last three months, shares of PetMed have been trading above the broader industry. The company has surged 33.1% compared with the broader industry’s 7.4% growth.
In second-quarter fiscal 2018, the company once again topped the Zacks Consensus Estimate on both revenues and earnings. We are also encouraged to note the stellar increase in reorder and new order sales in the period.
PetMed is striving to implement several strategies to revitalize its top line including its focus on advertising efficiency to boost new order sales as well as its sales shift to higher margin items while expanding the product portfolio.
However, we are apprehensive about the escalating advertising expenses incurred in fiscal second quarter. The company spent $4.5 million on advertising compared with $4.4 million for the same quarter last year.
The company markets its products, primarily under well-known brands of medication namely, Frontline Plus, K9 Advantix, Advantage, Heartgard Plus, Sentinel and Interceptor et al.
On the flip side, PetMed operates in a highly competitive and fragmented pet medications market with veterinarians, traditional retailers, other mail-order and online retailers of pet medications plus other health products dominating the space as its key competitors. Also, Eli Lilly and Company’s acquisition of Novartis' animal health division has led to more challenges for PetMed.
Akari has a projected growth rate of 88.89% for the next quarter. The earnings surprises delivered by the company have been positive in the last three quarters with an average beat of 88.6%.
Protagonist has an expected earnings growth rate of 36.9% in 2017. The stock has soared an impressive 80.6% in the last six months.
XOMA is expected to score an impressive earnings growth rate of 99.2% in 2017. The stock has skyrocketed a whopping 406.4% in the last 6 months, despite a loss of 1.7% incurred by the broader industry.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Image: Bigstock
PetMed Rides on Solid Reorders & New Orders Amid Competition
On Dec 29, we issued an updated research report on PetMed Express, Inc. (PETS - Free Report) . The stock sports a Zacks Rank #1 (Strong Buy).
Over the last three months, shares of PetMed have been trading above the broader industry. The company has surged 33.1% compared with the broader industry’s 7.4% growth.
In second-quarter fiscal 2018, the company once again topped the Zacks Consensus Estimate on both revenues and earnings. We are also encouraged to note the stellar increase in reorder and new order sales in the period.
PetMed Express, Inc. Price
PetMed Express, Inc. Price | PetMed Express, Inc. Quote
PetMed is striving to implement several strategies to revitalize its top line including its focus on advertising efficiency to boost new order sales as well as its sales shift to higher margin items while expanding the product portfolio.
However, we are apprehensive about the escalating advertising expenses incurred in fiscal second quarter. The company spent $4.5 million on advertising compared with $4.4 million for the same quarter last year.
The company markets its products, primarily under well-known brands of medication namely, Frontline Plus, K9 Advantix, Advantage, Heartgard Plus, Sentinel and Interceptor et al.
On the flip side, PetMed operates in a highly competitive and fragmented pet medications market with veterinarians, traditional retailers, other mail-order and online retailers of pet medications plus other health products dominating the space as its key competitors. Also, Eli Lilly and Company’s acquisition of Novartis' animal health division has led to more challenges for PetMed.
Other Key Picks
Some other top-ranked stocks from the broader medical space are Akari Therapeutics PLC. (AKTX - Free Report) , Protagonist Therapeutics Inc. (PTGX - Free Report) and XOMA Corporation (XOMA - Free Report) , each sporting the same bullish Zacks Rank of 1 as PetMed. You can see the complete list of today’s Zacks #1 Rank stocks here.
Akari has a projected growth rate of 88.89% for the next quarter. The earnings surprises delivered by the company have been positive in the last three quarters with an average beat of 88.6%.
Protagonist has an expected earnings growth rate of 36.9% in 2017. The stock has soared an impressive 80.6% in the last six months.
XOMA is expected to score an impressive earnings growth rate of 99.2% in 2017. The stock has skyrocketed a whopping 406.4% in the last 6 months, despite a loss of 1.7% incurred by the broader industry.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>